BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, May 10, 2025
Home » Authors » Marie Powers

Marie Powers

Articles

ARTICLES

Immunomedics, UCB Rework Agreement for Lupus Drug

Jan. 4, 2012
By Marie Powers
Immunomedics Inc. and development partner UCB SA revised their development, collaboration and license agreement for the exclusive worldwide rights to develop, market and sell Immunomedics' epratuzumab for autoimmune disease indications.
Read More

Roche Won't Move Avastin To FDA in Ovarian Cancer

Jan. 3, 2012
By Marie Powers
One week after the European Commission approved the use of Avastin (bevacizumab) in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer, findings from two Phase III studies published in the New England Journal of Medicine suggested the drug offered a modest but noticeable benefit over standard chemotherapy in terms of progression-free survival (PFS).
Read More

Immunomedics, UCB Rework Agreement for Lupus Drug

Dec. 29, 2011
By Marie Powers
Immunomedics Inc. and development partner UCB SA revised their development, collaboration and license agreement for the exclusive worldwide rights to develop, market and sell Immunomedics' epratuzumab for autoimmune disease indications.
Read More

Baxter, Momenta Ink Potential $470M Partnership for Six FOBs

Dec. 28, 2011
By Marie Powers
Baxter International Inc. and Momenta Pharmaceuticals Inc. jumped on the biosimilars bandwagon with a global collaboration to develop and commercialize up to six follow-on biologics (FOBs).
Read More

Exelixis, Sanofi Terminate Preclinical PI3K Programs

Dec. 27, 2011
By Marie Powers
A day after inking a potential $251 million agreement with Merck & Co. Inc. to license out its phosphoinositide-3 kinase (PI3K)-delta research and development program, Exelixis Inc. trimmed its pipeline further, agreeing to terminate the preclinical programs that were part of a blockbuster 2009 PI3K collaboration with Sanofi-Aventis SA, of Paris.
Read More

Exelixis Hands Merck PI3K-Delta Program in $251M Deal

Dec. 22, 2011
By Marie Powers
True to its word, Exelixis Inc. started to prune its pipeline this week, handing Merck & Co. Inc. an exclusive worldwide license to its phosphoinositide-3 kinase (PI3K)-delta research and development program, including XL499 – the company's most advanced preclinical PI3K-delta inhibitor – and related compounds.
Read More

NHGRI Seeks to Capitalize on Genome Sequencing Program

Dec. 21, 2011
By Marie Powers
The National Human Genome Research Institute (NHGRI) recently revealed an ambitious effort to capitalize on its flagship genome sequencing program by pumping $416 million into four areas over four years to find the causes of rare inherited diseases and to accelerate the use of genome sequence information in the medical care of patients.
Read More

Metamark, Janssen Biotech Ink Potential $365M Deal

Dec. 20, 2011
By Marie Powers
Privately held Metamark Genetics Inc. landed a big fish, inking a research, collaboration and license agreement with Johnson & Johnson subsidiary Janssen Biotech Inc. potentially worth $365 million.
Read More

Post-ASH, Ariad Prices Public Offering, Aims to Raise $224M

Dec. 16, 2011
By Marie Powers
On Wednesday, Ariad Pharmaceuticals Inc. filed a shelf registration covering stock, debt securities, warrants and units. The company didn't leave investors in suspense for long. A day later, the company priced an underwritten public offering of 21.5 million shares of common stock at Wednesday's closing price of $10.42 per share, a discount of just 5.4 percent from Tuesday's closing price of $11.01.
Read More

Salix Trumps Napo, Submits Crofelemer NDA for Review

Dec. 15, 2011
By Marie Powers
One month after partner Napo Pharmaceuticals Inc. claimed to terminate their three-year-old collaboration to develop crofelemer for HIV-associated diarrhea, Salix Pharmaceuticals Ltd. plowed ahead by submitting a new drug application (NDA) for the drug to the FDA. The filing set in motion the 60-day clock for the FDA to conduct its review and determine whether to accept the NDA.
Read More
View All Articles by Marie Powers

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 9, 2025.
  • US flag, stock market chart, White House

    100 days of uncertainty

    BioWorld
    The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • NME Digest: Q1 2025

    BioWorld
    A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing